# Sorafenib Concomitantly Used With TACE (Transarterial Chemoembolization) in uHCC (Unresectable Hepatocellular Carcinoma) Patients in China

> **NCT01839630** · — · COMPLETED · sponsor: **Bayer** · enrollment: 302 (actual)

## Conditions studied

- Carcinoma, Hepatocellular

## Interventions

- **DRUG:** Sorafenib (Nexavar, BAY43-9006)

## Key facts

- **NCT ID:** NCT01839630
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05-30
- **Primary completion:** 2016-08-06
- **Final completion:** 2016-12-29
- **Target enrollment:** 302 (ACTUAL)
- **Last updated:** 2017-12-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01839630

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01839630, "Sorafenib Concomitantly Used With TACE (Transarterial Chemoembolization) in uHCC (Unresectable Hepatocellular Carcinoma) Patients in China". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01839630. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*